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Abstract
Due to its low fractionation sensitivity, also known as “alpha/beta ratio,” in relation to its surrounding organs at risk,
prostate cancer is predestined for hypofractionated radiation schedules assuming an increased therapeutic ratio compared
to normofractionated regimens. While moderate hypofractionation (2.2–4Gy) has been proven to be non-inferior to normal
fractionation in several large randomized trials for localized prostate cancer, level I evidence for ultrahypofractionation
(>4Gy) was lacking until recently. An accumulating body of non-randomized evidence has recently been strengthened
by the publication of two randomized studies comparing ultrahypofractionation with a normofractionated schedule, i.e.,
the Scandinavian HYPO-RT trial by Widmark et al. and the first toxicity results of the PACE-B trial. In this review, we
aim to give a brief overview of the current evidence of ultrahypofractionation, make an overall assessment of the level of
evidence, and provide recommendations and requirements that should be followed before introducing ultrahypofractionation
into routine clinical use.
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External beam radiation (EBRT) is one of the mainstays of
the treatment of prostate cancer of all risk groups, to all
patients who are in the decision-making process of which
treatment to choose. This decision has become more com-
plex recently, since many—equally effective—treatment al-
ternatives are available, including active surveillance or de-
ferred treatment for low-risk (LR) disease. The fact that
LR prostate cancer bears a high risk of overtreatment is
now unanimously addressed in current relevant guidelines
and translates into de-escalated treatment regimens where
potential side effects are very carefully weighed against
the benefits of a given therapy. In contrast, high-risk (HR)
prostate cancer still represents a potentially lethal disease
demanding more aggressive treatment.
In this light, ultrahypofractionation qualifies as a viable
option in the primary treatment of localized prostate can-
cer, since it can be tailored to the risk status in terms of
fractional and total dose, with or without androgen depri-
vation therapy. In a situation where LINAC capacities are
limited in many countries (or reduced as a side effect of the
current COVID-19 pandemic), possibilities to reduce treat-
ment time or fractions without compromising outcome are
highly sought after. At the same time, ultrahypofractiona-
tion offers a high level of patient convenience due to low
overall treatment times without an excess of toxicity. Thus,
it is viewed as an attractive alternative to surgery.
In this review we recapitulate the more recent literature
(randomized evidence and meta-analyses) on ultrahypofrac-
tionation, put it into context with current recommendations,
and provide principles which should be followed before in-
troducing ultrahypofractionation into clinical routine.
Terminology
Extreme or ultrahypofractionation is commonly used syn-
onymously with stereotactic body radiation therapy (SBRT)
and stereotactic ablative body radiation (SABR), although
the former terms strictly refer to the fraction size, whereas
the latter also refer to the platform of beam delivery and
radiation technique. We therefore chose to use the term ul-
trahypofractionation for all forms of delivery of more than
4Gy per fraction.
The American Society for Radiation Oncology (ASTRO),
American Society of Clinical Oncology (ASCO), and
American Urological Association (AUA) hypofractiona-
tion guideline [1] defines moderate hypofractionation as
2.4–3.4Gy/fraction and ultrahypofractionated radiotherapy
as doses per treatment of 5.0Gy/fraction or higher, thus
leaving a “grey zone” between 3.4 and 5Gy.
The Prostate Cancer Expert Panel of the German Society
of Radiation Oncology (DEGRO) and the Working Party
Radiation Oncology of the German Cancer Society (DKG-
ARO) use a definition of 2.2–4Gy/fraction for moderate
and beyond 4Gy/fraction for ultrahypofractionation [2].
Ultrahypofractionation is usually delivered using high-
precision techniques (LINAC based or CyberKnife [Accu-
ray Inc. Sunnyvale, CA, USA]) aided by daily image guid-
ance including adequate motion management strategies al-
lowing for small PTV margins and high dose conformation.
Radiobiology
While for most cancer types a normofractionation sched-
ule of 1.8–2Gy per day/five times a week represents the
sweet spot in terms of tumor control and toxicity, some
tumors exhibit a higher sensitivity to fractional doses and
might therefore benefit from hypofractionated schedules.
This property is reflected by a low alpha/beta (α/β) value
and can be quite accurately described with the so-called
linear-quadratic model [3]. The α/β value is a measure of
fractionation sensitivity and is related to the inherent capac-
ity of tumor cells to repair sublethal DNA damage inflicted
by ionizing radiation.
Whether hypofractionation is beneficial depends on the
α/β values of the target in relation to its surrounding normal
tissues. For prostate cancer cells, very low α/β values of
about 1.5Gy have been derived from multiple preclinical
and clinical studies [4–9]. Late toxicity of the bladder and
rectum has been estimated to have an α/β value of 5.6Gy
[10, 11] and 3Gy [3, 12], respectively. Therefore, in theory,
hypofractionated radiation schedules should have a benefi-
cial effect on the therapeutic ratio.
More recent data have shown that in addition to frac-
tion dose, overall treatment time seems to play a major
role [13], which has been neglected in the aforementioned
calculations of the α/β ratio ([14] reviewed in [15]). When
a time factor is accounted for in the calculation, slightly
higher α/β values will result, so that many authors nowa-
days endorse values of approximately 2–2.7Gy. In a recent
meta-analysis, Vogelius and Bentzen calculated α/β values
based on 13 randomized trials with and without the pres-
ence of a time factor of 0.31Gy loss per day, yielding
α/β values of 1.2Gy and 2.7Gy, respectively. Of note, the
higher α/β derived from hypofractionated dose escalation
studies might in part be contributed to the fact that the
dose–response relationship starts to max out at approxi-
mately EQD2 80Gy—a dose which is superseded by most
ultrahypofractionation regimens [16]. It also needs to be
emphasized that when comparing EQD2’s of different frac-
tionation regimens using the time-corrected α/β value, only
regimens with the same overall treatment time should be
compared. For that reason, we chose to use an α/β value
of 2Gy in the present manuscript, in order to appreciate
that ultrahypofractionation regimens have a considerably
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reduced overall treatment time (mostly roughly 2 weeks)
compared to normofractionated and moderately hypofrac-
tionated regimens.
Cost effectiveness
In addition to its potential benefit in terms of the therapeu-
tic ratio, ultrahypofractionation may reduce treatment cost
for prostate cancer, which, due to its high prevalence, has
a major impact on general health care expenses.
It has been shown that ultrahypofractionation is asso-
ciated with lower overall treatment costs than normofrac-
tionated 3D conformal or IMRT [17] as well as moderate
hypofractionation [18]. In a recent systemic review com-
prising 12 studies, Abreha et al. [19] performed a model-
based cost-effectiveness analysis confirming that ultrahy-
pofractionation is the most effective treatment in terms of
overall treatment cost, including prostatectomy.
However, most available studies are based on the US
Medicare system. For Europe, treatment costs can differ
dramatically but there is reason to assume that the relations
between different modalities remain similar [20].
Moderate hypofractionation
For low- and intermediate-risk (IR) prostate cancer, mod-
erate hypofractionation has been shown to be non-inferior
to normofractionated treatment in several prospective ran-
domized trials [21–24], and is now strongly recommended
in the primary setting by NCCN guidelines [25] and viewed
as a viable alternative in current EAU [21] and German
S3 guidelines (https://www.leitlinienprogramm-onkologie.
de/leitlinien/prostatakarzinom/). The latter two explicitly
advise its performance only by experienced teams using
high-quality EBRT (IGRT and IMRT) in carefully selected
patients, with strong adherence to published phase III pro-
tocols.
For HR patients, the benefit of hypofractionated ra-
diotherapy is less clear. Analyses from three large meta-
analyses [6–8] comprising more than 20,000 patients have
yielded low α/β values for all risk groups, which led Fowler
et al. to conclude that “the low α/β ratio is an intrinsic
property of all prostate cancer cells irrespective of their
Gleason score or grading” [26]. However, clinical data to
support this notion are still lacking. In the three large non-
inferiority trials [22–24], HR patients were underrepre-
sented. In the superiority design HYPRO trial [25], HR
patients were included, but the primary endpoint (improved
biochemical control at 5 years) did not reach significance




The Scandinavian trial (HYPO-RT-PC)
The Scandinavian non-inferiority design HYPO-RT-PC
trial by Widmark et al. [26] randomized men with IR
to HR prostate cancer to receive either 42.7Gy in seven
fractions, 3 days per week, or conventionally fractionated
radiotherapy (78Gy in 39 fractions, 5 days per week).
After a median follow-up of 5 years, failure-free survival
was identical (84%) in both arms. Acute RTOG G2 or
worse genitourinary (GU) toxicity was slightly but not
significantly increased in the ultrahypofractionated arm
at the end of treatment (28% vs. 23%, p= 0.057). A sig-
nificant rise was only seen at 1-year follow-up (6% vs.
2%, p= 0.0037), disappearing completely at timepoints
thereafter (5-year rate: 5% in both arms). There was no
difference in gastrointestinal (GI) toxicity at any timepoint
and no differences in toxicity after 5 years.
Of note, the Widmark trial features some peculiarities
and differences compared to the abundant but retrospective
trial protocols that have accumulated in the past decade.
These differences need to be critically reviewed before rou-
tine clinical application:
1. It excluded LR and included intermediate- and high-risk
patients: to our knowledge, theWidmark study is the only
ultrahypofractionation study in which LR patients were
excluded. In addition, a particular subset of HR patients
(PSA <20ng/ml and T3a) were included (11%), which
is in stark contrast to the low percentage of HR patients
treated within the published retrospective series.
2. It used seven instead of the commonly reported five frac-
tions, which is unique among the ultrahypofractionation
trials.
3. No androgen deprivation therapy (ADT) was given: In
both arms, ADT was withheld to all patients, which
might have had a negative impact on progression-free
survival (PFS) as well as overall survival (OS) for (un-
favorable) IR and HR patients. For these risk groups,
there is no evidence that either hypofractionation or dose
escalation (or both) can compensate for the lack of ADT
which is known to improve both biochemical control as
well as OS [27].
4. The LINAC-based radiation technique did not have to
meet highest standards. Neither MR imaging for contour-
ing nor treatment by IMRT were mandatory. In fact, 80%
of patients were treated with conventional 3D planning
(commented in [28]).
5. Contouring and margins: Seminal vesicles were not in-
cluded in the CTV, which is questionable since EORTC
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guidelines recommend including the proximal 1–2cm
for IR and HR patients, respectively [29]. PTV margins
were rather large (7mm) even though image guidance
was used using either BeamCathTM (Beampoint AB,
Kista, Sweden) (10%) or gold fiducials (90%).
PACE-B
Early toxicity results of the randomized PACE-B trial have
recently been published [30].
In that non-inferiority trial, men with LR or IR prostate
cancer (Gleason 7b excluded) received either conventional
or moderately hypofractionated radiotherapy (78Gy in
39 fractions in 7–8 weeks or 62Gy in 20 fractions over
4 weeks, respectively) or SBRT (36.25Gy in five fractions
over 1–2 weeks). ADT was not permitted.
A total of 41% of patients in the SBRT arm were treated
with CyberKnife, 58.3% with a conventional LINAC using
volumetric arc therapy (VMAT). IGRT and intra-fractional
motion control were mandatory.
In terms of acute toxicity there was no significant dif-
ference between the arms, but a slight trend in favor of the
SBRT arm (23% vs. 27%). This is in contrast to the Wid-
mark trial, where a trend toward increased acute toxicity
was seen in the ultrahypofractionated arm.
Meta-analyses of non-randomized prospective data
Well over 10,000 patients have been treated within ultrahy-
pofractionated non-randomized prospective protocols, with
large variations in fraction size, total dose, and radiation
technique. The most relevant studies based on quality and
patient cohort size have been summarized and re-analyzed
by three large pooled analyses [31–33].
King et al. 2013
The first pooled analysis by King et al. [31] included
1100 patients from eight institutions who had been treated
within prospective phase II trials using CyberKnife with
a median follow-up of 36 months. They received a median
dose of 36.25Gy in 4–5 fractions. LR (58%), IR (30%), and
HR (11%) patients were included. A short course of ADT
was given to 14% of patients. The five-year biochemical
relapse-free survival (bRFS) rate was 93% for all patients
and 95%, 84%, and 81% for LR, IR, and HR patients,
respectively (p< 0.001). Toxicity was not reported.
Kishan et al. 2019
The second analysis is a cohort study Kishan et al. [32]
which analyzed individual patient data from 12 phase II tri-
als comprising 2142 men with LR and IR prostate cancer
treated with either CyberKnife (7/12 studies) or a conven-
tional LINAC (5/12 studies). 55.3% of patients had LR
disease, 32.3% had favorable IR disease, and 12.4% unfa-
vorable IR disease. HR patients were excluded. The follow-
up period was quite long, with a median of 6.9 years.
Seven-year biochemical recurrence-free survival (bRFS)
amounted to 95.5% for LR disease and 89.8% for IR dis-
ease. The crude incidence of acute grade 3 or higher toxic
events was 0.60% for GU and 0.09% for GI side effects.
Jackson et al. 2019
The most recent and more extensive review was under-
taken by Jackson et al. [33], comprising 6116 patients from
38 prospective studies. There was a large patient overlap
with the patient collectives of the former two analyses by
King and Kishan et al. A meta-analysis using random ef-
fect modeling was performed on a study-level basis. Only
studies reporting the same outcome at the same timepoint
were pooled, which is an inherent limitation.
At the patient level, 45% had LR, 47% had IR, and 8%
HR disease. Median follow-up was 39 months, but 5- and
7-year bRFS rates and toxicities were reported, not com-
plying with the RTOG-ASTRO Phoenix consensus, which
recommends the reported date of control be listed as 2 years
short of the median follow-up [34].
Combined acute ≥G3 toxicity was below 1%. Late ≥G3
GU and GI toxicity was 2.0% and 1.1%, respectively, and
did not change when only studies with a median FU of
≥5years were analyzed. There was a significant publication
bias, which, when corrected for, increased toxicity rates by
1 to 2%. Interestingly, there was an association of dose with
late grade ≥G3 GU toxicity but not with ≥G3 GI toxicity.
The authors conclude that ultrahypofractionation could be
considered a standard radiotherapeutic strategy for localized
prostate cancer—maybe a premature statement given how
underrepresented HR patients were in that study.
Treatment of the primary in low-volumemetastatic
disease setting
Two recent prospective randomized trials (HORRAD [35]
and STAMPEDE [36]) have addressed the role of RT to
the prostate in metastatic disease. Ultrahypofractionation is
an appealing option in this scenario and has been used op-
tionally in the STAMPEDE trial in which 48% of patients
were treated with 36Gy in 6 weekly fractions correspond-
ing to an equivalent dose in 2Gy fractions (EQD2α/β 2 Gy) of
72Gy. The STAMPEDE subgroup analysis of low-volume
metastatic disease demonstrated a survival advantage in fa-
vor of the RT arm (hazard ratio 0.68; 95% CI 0.52–0.90).
The HORRAD trial showed a similar but non-significant
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Table 1 Treatment schedules and corresponding EQD2 for different α/β values
Dose/fx No. fx Total dose EQD2 α/β 1.5 EQD2 α/β 2 EQD2 α/β 3 EQD2 α/β 10
HYPO-RT-PC [26] 6.1 7 42.7 92.72 86.47 77.71 57.29
PACE [30] 7.25 5 36.25 90.63 83.83 74.31 52.11
Median fx Jackson
et al. [33]
7.4 5 37 94.09 86.95 76.96 53.65
STAMPEDE primary
metastatic [36]
6 6 36 77.14 72.00 64.80 48.00
fx fraction, EQD2 equivalent dose in 2Gy fractions
trend towards an improved OS by RT (hazard ratio 0.68;
95% CI 0.42–1.10). As a result, the 2019 European As-
sociation of Urology and National Comprehensive Cancer
Network guidelines now include RT to the prostate as an
option in the setting of low-volume metastatic disease [37].
Interpretation
An accumulating body of retrospective evidence for the
safety and efficacy of SBRT for LR and IR prostate can-
cer has recently been strengthened by the publication of two
randomized studies comparing SBRT with a normofraction-
ated schedule, i.e., the Scandinavian trial by Widmark et al.
[26] and the first toxicity results of the PACE-B trial [30].
Since the PACE study has not yet reached sufficient follow-
up to report on outcome or late toxicity, the Scandinavian
trial is thus far the only randomized trial comparing an ul-
trahypofractionated to a normofractionated schedule with
reported long-term (i.e., 5 years) outcome and toxicity. It
is therefore the only level Ib evidence (according to the
Oxford Centre for Evidence-Based Medicine, https://www.
cebm.net/index.aspx?o=5653) available and has raised the
grade of recommendation from C to B. This could justify
the clinical use of ultrahypofractionation outside of clinical
trials for low- and intermediate-risk prostate cancer.
HR patients should continue to be treated within clinical
trials due to several reasons: First, the body of evidence for
LR and IR prostate cancer is overwhelmingly larger than for
HR prostate cancer patients constituting well below 8% of
studied patients. In addition, it remains disputable whether
Gleason 8–10 prostate cancer cells feature an equally low
α/β value, although this has been postulated [38]. Third, ul-
trahypofractionation of the prostate hampers simultaneous
coverage of pelvic lymph nodes. Pelvic RT in HR patients
is endorsed by many institutions, although its value is still
controversially discussed. However, an ultrahypofraction-
ated boost with reduced dose after whole pelvic RT might
be an attractive concept [39, 40].
ADT has been used inconsistently in the available ul-
trahypofractionation trials. However, at the present time
there is no evidence that high dose can compensate for the
lack of ADT in higher-risk prostate cancer. Therefore, ADT
should be administered according to the current guidelines,
i.e., short-term ADT (4–6 months) for unfavorable IR and
long-term ADT (18–36 months) for HR prostate cancer.
For favorable IR the omission of ADT seems appropriate
in a dose-escalated setting [27].
For ultrahypofractionation, the ideal fractionation regi-
men has not yet been established. A variety of schedules
have been published and can be considered safe (see Table 1
for select examples and corresponding EQD2s for different
α/β values). With the exception of the Scandinavian trial by
Widmark et al., most larger series used doses of 36.25 to
40Gy in five fractions administered every other day. In the
meta-analysis by Jackson et al., the median fraction size
was 7.4Gy. For unfavorable IR patients, slightly higher to-
tal doses may be considered. The seven-fraction schedule
by Widmark et al. has been tested in a randomized prospec-
tive fashion and can be considered a viable option for IR
patients.
For treatment of the primary in the metastatic setting, ul-
trahypofractionation is an attractive alternative to moderate
hypofractionation and has been tested in the STAMPEDE
trial. Prolongation of the overall treatment time to 6 weeks
is rather unusual for an ultrahypofractionated regimen and
may be the reason why in this trial, the alternatively used
moderately hypofractionated radiation schedule of 55Gy in
20 fractions (daily) showed a slightly better outcome (not
significant, HR 0.86 vs. 1.01).
Compared to radiation schedules in the non-metastatic
setting, the resulting BEDs of these doses are rather con-
servative, which owes to the palliative setting where the
maxim primum non nocere is to be followed strictly. In
general, further studies are needed to establish an appropri-
ate fractionation schedule in the metastasized setting, but if
ultrahypofractionation is used, the DEGRO Prostate Cancer
Expert Panel favors every-other-day schedules over once-
weekly regimens and recommends aiming for a total dose
of at least EQD2α/β2 72Gy.
Conclusion
Retrospective as well as randomized prospective data with
a follow-up of 5 years or more are now available and have
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shown comparable results to recent moderate hypofraction-
ation trials in terms of both biochemical control and toxi-
city. Although level Ib evidence for ultrahypofractionation
is now available, the DEGRO prostate cancer expert panel
does not yet recommend ultrahypofractionation for HR pa-
tients on a routine basis. However, for centers that are ex-
perienced in SBRT and wish to offer ultrahypofractionation
to selected LR and IR patients, this seems justified outside
of a clinical trial (grade B recommendation).
In interpretation of the published data, the following
principles should be followed when administering ultrahy-
pofractionation in prostate cancer in clinical routine.
1. Ultrahypofractionation is a treatment alternative, amongst
moderate hypofractionation and normofractionation,
which can be offered outside clinical trials to LR pa-
tients who are not suitable for active surveillance and for
IR patients including both favorable and unfavorable IR.
2. ADT should be administered according to current guide-
lines for normo- and moderately hypofractionated regi-
mens, i.e., short-term ADT for unfavorable IR (and long-
term ADT for HR patients). For favorable IR, dose-esca-
lated RT alone appears to be an appropriate treatment.
3. Ultrahypofractionation should be administered in a set-
ting of high technical standards. We consider MR-
based planning, IMRT/VMAT, and daily IGRT with
basic intrafractional control (i.e., imaging after 3min of
treatment time) as minimum requirements in order to
safely achieve PTV margins of approximately 3mm. In
a LINAC-based setting, short treatment times need to be
pursued using single-arc VMAT and/or flattening filter-
free (FFF) techniques.
4. Dose schedules should strictly adhere to published con-
cepts of larger studies. A maximum fraction size of 8Gy
and a maximum EQD2α/β2 of 100Gy should not be ex-
ceeded. In the curative, non-metastatic setting, a mini-
mum EQD2α/β2 of 83.3Gy (e.g., 5× 7.25Gy) is required.
See Table 1 for different fractionation schedules and cor-
responding EQD2s at different α/β values.
5. For treatment of the primary in the metastatic setting,
ultrahypofractionation may be used as an alternative to
moderate hypofractionation. However, slightly de-es-
calated schedules with an EQD2α/β2 of approximately
72–76Gy should be used.
6. Patients should be followed up by the treating facility for
at least 5 years. Inclusion in a registry study is recom-
mended.
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